Company intelligence / Profile preview

Corsair Capital

Sunnyvale, California, United Statescorsair-capital.com ↗

Ownership: Private
Development stage: Other

Overview

Corsair Pharma is developing a once-daily transdermal patch delivering a prodrug of treprostinil for pulmonary arterial hypertension. The approach aims to provide continuous drug levels comparable to infusion pumps but with non-invasive administration and potentially improved side effect profile. As of September 2023, the company had closed a $23 million Series B financing round to advance its lead program into clinical trials.

Therapeutic areas: Cardiovascular
Modalities: Small moleculeProdrugTransdermal patch (Device/Drug combination)
Industry: Biotech

Partnerships

United Therapeutics (strategic partnership in PAH therapies)

Beyond the preview

Go deeper on Corsair Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Corsair Capital.

Explore the full profile